Ascletis Pharma's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 60.61.
Ascletis Pharma's Days Inventory for the
six
months ended in Dec. 2025 was 1126.22.
Ascletis Pharma's Days Payable for the
six
months ended in Dec. 2025 was 232.93.
Therefore, Ascletis Pharma's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 953.90.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Ascletis Pharma Cash Conversion Cycle Related Terms
Ascletis Pharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Ascletis Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Ascletis Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Cash Conversion Cycle of 953.90 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Ascletis Pharma and its competitors.
Is Ascletis Pharma's Cash Conversion Cycle too high?
Ascletis Pharma's current Cash Conversion Cycle is 953.90. The Biotechnology industry median Cash Conversion Cycle is 103.69. Ascletis Pharma's value of 953.90 is 820% above this industry median. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Cash Conversion Cycle compare to VRTX and REGN?
Ascletis Pharma's Cash Conversion Cycle of 953.90 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Ascletis Pharma's value of 953.90 is 820% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Cash Conversion Cycle of 953.90 is 820% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Cash Conversion Cycle is 953.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Cash Conversion Cycle is 953.90 and 820% above the Biotechnology industry median of 103.69. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Cash Conversion Cycle is 953.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Cash Conversion Cycle: 953.90
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
Industry Position: 820% above the Biotechnology median
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
